Like natives encountering a strange explorer in an old B movie, investors hailed Jeffrey Kindler (photo [1]) when he was picked to succeed Pfizer CEO Hank McKinnell. Now, 19 months into his tenure, the natives are getting restless. Kindler hasn't delivered the kind of sweeping change he promised. Report [2]